drugset / Trial / NCT04533347

Tafenoquine in Patients With Mild to Moderate COVID-19

NCT04533347

Phase 2 Completed 86 enrolled 60 Degrees Pharmaceuticals LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.

Timeline

Start
2021-02-19
Primary completion
2022-06-30
Completion
2022-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tafenoquine Small molecule 200 mg Oral

Indications